248 related articles for article (PubMed ID: 19212608)
1. Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection.
Verburg FA; de Keizer B; de Klerk JM; Lentjes EG; Lips CJ; van Isselt JW
Nuklearmedizin; 2009; 48(1):26-9. PubMed ID: 19212608
[TBL] [Abstract][Full Text] [Related]
2. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
3. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
[TBL] [Abstract][Full Text] [Related]
6. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.
Pacini F; Lippi F
J Endocrinol Invest; 1999; 22(11 Suppl):25-9. PubMed ID: 10727002
[TBL] [Abstract][Full Text] [Related]
8. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
Kohlfuerst S; Igerc I; Lind P
Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
[TBL] [Abstract][Full Text] [Related]
13. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
Caresia AP; Castell Conesa J; Obiols Alfonso G; Pifarré Montaner P; Negre Busó M; García Alonso C; Galofré Mora P; Mesa Manteca J
Rev Esp Med Nucl; 2006; 25(4):236-41. PubMed ID: 16827986
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of recombinant human thyrotropin application in following-up patients with well-differentiated thyroid carcinoma].
Rajkovaca Z; Kovacević P; Stanetić M; Ristić S
Vojnosanit Pregl; 2012 Nov; 69(11):941-6. PubMed ID: 23311243
[TBL] [Abstract][Full Text] [Related]
17. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.
Eustatia-Rutten CF; Smit JW; Romijn JA; van der Kleij-Corssmit EP; Pereira AM; Stokkel MP; Kievit J
Clin Endocrinol (Oxf); 2004 Jul; 61(1):61-74. PubMed ID: 15212646
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
Torlontano M; Crocetti U; Augello G; D'Aloiso L; Bonfitto N; Varraso A; Dicembrino F; Modoni S; Frusciante V; Di Giorgio A; Bruno R; Filetti S; Trischitta V
J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
